The Asia Pacific Hemostats Market is expected to witness market growth of 5.8% CAGR during the forecast period (2022-2028).
Several manufacturers presently offer licensed hemostatic powders for adult usage, primarily for upper gastrointestinal bleeding. In order to stop bleeding after polypectomy, as well as from colonic tumors, diverticula, arteriovenous malformations, radiation proctitis, ischemic colitis, & surgical intestine anastomosis, hemostatic powders were employed as both a primary and salvage therapy. The use of local hemostatic medicines in lower gastrointestinal bleeding seems to have several potential benefits, particularly in terms of their ease of administration, although additional randomized controlled trials are still required.
The hemostatic system has developed to play a crucial part in preserving a vulnerable balance between keeping the blood in a fluid state to ensure uninterrupted flow at all times and reacting to any disturbance of the vascular consistency so that extravasation is swiftly arrested by the formation of a hemostatic plug. The delicate equilibrium is thrown off by variations in blood flow, the vessel wall, and the soluble and cellular components of blood, which can result in thrombus development (thrombosis).
Due to investments made in the infrastructure development of the healthcare sectors in emerging economies, the Asia Pacific market will benefit significantly. The industry is currently looking for an ideal treatment scenario as a result of which the newest products are approved very quickly. The market has more chance to expand as a result of the rising disposable income of people. Additionally, the area has established itself as a center for medical tourism. Players in the Indian hemostat market should benefit from lucrative growth prospects due to the rising popularity of out-patient operations.
The China market dominated the Asia Pacific Hemostats Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $296.9 million by 2028. The Japan market is estimated to grow a CAGR of 5.2% during (2022 - 2028). Additionally, The India market is expected to experience a CAGR of 6.5% during (2022 - 2028).
Based on Application, the market is segmented into Orthopedic Surgery, General Surgery, Neurological Surgery, Cardiovascular Surgery, Reconstructive Surgery, Gynecological Surgery, and Others. Based on Formulation, the market is segmented into Matrix & Gel, Sheet & Pad, Powder, Sponge, and Others. Based on Type, the market is segmented into Thrombin Based, Combination, Oxidized Regenerated Cellulose Based, Gelatin Based, Collagen Based, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Becton, Dickinson and Company, Baxter International, Inc., B. Braun Melsungen AG, Teleflex, Inc., Medtronic PLC, Johnson & Johnson, Pfizer, Inc., Stryker Corporation, Integra LifeSciences Holdings Corporation, and Artivion, Inc.
Several manufacturers presently offer licensed hemostatic powders for adult usage, primarily for upper gastrointestinal bleeding. In order to stop bleeding after polypectomy, as well as from colonic tumors, diverticula, arteriovenous malformations, radiation proctitis, ischemic colitis, & surgical intestine anastomosis, hemostatic powders were employed as both a primary and salvage therapy. The use of local hemostatic medicines in lower gastrointestinal bleeding seems to have several potential benefits, particularly in terms of their ease of administration, although additional randomized controlled trials are still required.
The hemostatic system has developed to play a crucial part in preserving a vulnerable balance between keeping the blood in a fluid state to ensure uninterrupted flow at all times and reacting to any disturbance of the vascular consistency so that extravasation is swiftly arrested by the formation of a hemostatic plug. The delicate equilibrium is thrown off by variations in blood flow, the vessel wall, and the soluble and cellular components of blood, which can result in thrombus development (thrombosis).
Due to investments made in the infrastructure development of the healthcare sectors in emerging economies, the Asia Pacific market will benefit significantly. The industry is currently looking for an ideal treatment scenario as a result of which the newest products are approved very quickly. The market has more chance to expand as a result of the rising disposable income of people. Additionally, the area has established itself as a center for medical tourism. Players in the Indian hemostat market should benefit from lucrative growth prospects due to the rising popularity of out-patient operations.
The China market dominated the Asia Pacific Hemostats Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $296.9 million by 2028. The Japan market is estimated to grow a CAGR of 5.2% during (2022 - 2028). Additionally, The India market is expected to experience a CAGR of 6.5% during (2022 - 2028).
Based on Application, the market is segmented into Orthopedic Surgery, General Surgery, Neurological Surgery, Cardiovascular Surgery, Reconstructive Surgery, Gynecological Surgery, and Others. Based on Formulation, the market is segmented into Matrix & Gel, Sheet & Pad, Powder, Sponge, and Others. Based on Type, the market is segmented into Thrombin Based, Combination, Oxidized Regenerated Cellulose Based, Gelatin Based, Collagen Based, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Becton, Dickinson and Company, Baxter International, Inc., B. Braun Melsungen AG, Teleflex, Inc., Medtronic PLC, Johnson & Johnson, Pfizer, Inc., Stryker Corporation, Integra LifeSciences Holdings Corporation, and Artivion, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Orthopedic Surgery
- General Surgery
- Neurological Surgery
- Cardiovascular Surgery
- Reconstructive Surgery
- Gynecological Surgery
- Others
By Formulation
- Matrix & Gel
- Sheet & Pad
- Powder
- Sponge
- Others
By Type
- Thrombin Based
- Combination
- Oxidized Regenerated Cellulose Based
- Gelatin Based
- Collagen Based
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Becton, Dickinson and Company
- Baxter International, Inc.
- B. Braun Melsungen AG
- Teleflex, Inc.
- Medtronic PLC
- Johnson & Johnson
- Pfizer, Inc.
- Stryker Corporation
- Integra LifeSciences Holdings Corporation
- Artivion, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Hemostats Market by Application
Chapter 4. Asia Pacific Hemostats Market by Formulation
Chapter 5. Asia Pacific Hemostats Market by Type
Chapter 6. Asia Pacific Hemostats Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Becton, Dickinson and Company
- Baxter International, Inc.
- B. Braun Melsungen AG
- Teleflex, Inc.
- Medtronic PLC
- Johnson & Johnson
- Pfizer, Inc.
- Stryker Corporation
- Integra LifeSciences Holdings Corporation
- Artivion, Inc.
Methodology
LOADING...
